HNSCC : Bulletin #2
Gain new KOL insights on the latest events happening in head and neck squamous cell carcinoma (HNSCC): data from the Phase I/II ECHO-202/KEYNOTE-037 study of Incyte’s IDO1 inhibitor epacadostat in combination with Keytruda (pembrolizumab; Merck & Co.) were presented at ASCO 2017; preliminary results from the ongoing Phase I/II ECHO-204 trial of epacadostat plus Opdivo (nivolumab; Bristol-Myers Squibb [BMS]) in patients with solid tumours, including HNSCC, were presented at ASCO 2017; Merck & Co. announced that the Phase III KEYNOTE-040 trial of Keytruda in previously treated patients with recurrent or metastatic HNSCC failed to meet its primary endpoint of overall survival (OS).
How do KOLs view the data from the Phase I/II ECHO-202/KEYNOTE-037 study of epacadostat in combination with Keytruda?
Where will Keytruda/epacadostat be most likely used in the HNSCC treatment algorithm?
How do KOLs view the data from the Phase I/II ECHO-204 trial of epacadostat in combination with Opdivo?
What potential does Opdivo/epacadostat hold as a treatment approach for HNSCC and where will it be most likely incorporated into the treatment paradigm?
How does Keytruda/epacadostat compare with Opdivo/epacadostat as potential combination treatment regimens for HNSCC?
How do KOLs interpret the failure of the KEYNOTE-040 trial of Keytruda to meet its primary endpoint of OS and what bearing will this have on its continued use in second-line treatment?
Please Note: Due to the brevity and/or nature of the content posted, there is no table of contents available for this report.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook